CPT 82234: Beta–Amyloid 42 Assay, Laboratory Chemistry

CPT code 82234 denotes a laboratory chemistry test quantifying beta–amyloid 42, a biomarker relevant to Alzheimer’s disease evaluation. As biomarker testing expands in clinical neurology and research settings, reliable coding for specialized assays like beta–amyloid 42 supports appropriate billing, claims adjudication, and broader surveillance of diagnostic utilization across the country. Payers addressed in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

This article provides a concise overview of CPT code 82234, explaining the clinical context of beta–amyloid 42 testing, the typical laboratory service setting, and why accurate coding matters for clinical workflows and payer processing. Readers will find benchmarks for payer coverage where available, a summary of common billing modifiers, and notes on clinical relevance to Alzheimer’s disease diagnosis and management. Where input data is unavailable, the publication explicitly notes those gaps. The piece is written for a national audience of billing professionals, laboratory directors, and policy analysts seeking a clear, practical reference on coding and clinical context for beta–amyloid 42 assays.

Billing Code Overview

CPT code 82234 describes a laboratory chemistry assay for beta–amyloid 42, a protein biomarker used in the evaluation of Alzheimer’s disease pathology. The service reflects analysis performed by a lab analyst to quantify beta–amyloid 42 concentration in a patient specimen.

Service type: Laboratory chemistry assay

Typical site of service: Clinical laboratory or hospital laboratory

Data not available in the input.

Clinical Context

A 72-year-old patient with progressive short-term memory loss and concerns for early Alzheimer disease is referred by a neurologist for cerebrospinal fluid (CSF) biomarker testing. The patient presents to an outpatient neurology clinic; CSF is obtained via lumbar puncture by the neurologist or interventional radiologist and the specimen is sent to a clinical chemistry laboratory. The laboratory analyst performs a quantitative assay for beta-amyloid 42 to evaluate amyloid pathology as part of a biomarker panel that may also include total tau and phosphorylated tau. Results are reported to the ordering clinician and integrated with clinical exam, neuroimaging, and neuropsychological testing to support diagnostic evaluation and care planning. Typical site of service: hospital outpatient laboratory or independent clinical laboratory associated with an ambulatory neurology clinic.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional component (interpretation or supervision) if applicable for lab-based consultation.
`TC`	Technical component	Use when billing only the technical component for the laboratory testing process and supplies.

Taxonomy Code	Specialty	Notes
207RH0000X	Neurology	Neurologists commonly order CSF beta-amyloid testing for Alzheimer disease evaluation.
2080P0207X	Clinical Pathology	Pathologists and clinical laboratory specialists oversee assay validation and result interpretation.
332B00000X	Nurse Practitioner	Advanced practice providers in neurology clinics may order testing and coordinate specimen collection.
363L00000X	Clinical Laboratory Scientist	Laboratory professionals who perform and validate the `82234` chemistry assay.
208D00000X	Diagnostic Radiology	Interventional radiologists may perform image-guided lumbar puncture when needed.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G30.0`	Alzheimer's disease with early onset	Amyloid biomarker testing is relevant for diagnostic confirmation in suspected early Alzheimer disease.
`G30.1`	Alzheimer's disease with late onset	Common indication for beta-amyloid 42 testing to support diagnosis in older adults.
`G31.84`	Mild cognitive impairment, so stated	Beta-amyloid testing helps stratify risk of progression to Alzheimer disease.
`F02.80`	Dementia in other diseases classified elsewhere without behavioral disturbance	Used when dementia is present and biomarkers may assist in etiologic evaluation.
`R41.3`	Other amnesia	When memory loss is a presenting symptom, CSF amyloid testing may be part of assessment.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`83876`	Immunoassay for infectious agent antigen detection	Performed for other CSF antigen testing when infectious causes are considered in differential diagnosis.
`84133`	Assay of creatine kinase (CK)	Example of a chemistry analyte; listed as a contemporaneous laboratory chemistry test that may be ordered on CSF or serum.
`62270`	Spinal puncture, lumbar, diagnostic	Procedure code for lumbar puncture used to obtain CSF specimen prior to laboratory testing.
`80053`	Comprehensive metabolic panel	Common laboratory panel ordered concurrently to assess systemic contributors to cognitive decline.
`S3993`	Laboratory test, interpretive services (varies by payer)	Represents professional interpretive services associated with specialized biomarker testing when billed separately.

OpenPayer

Summary & Overview